From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (J.B.P., M.W.F.).
Feinberg School of Medicine, Northwestern University, Chicago, IL (J.B.P.).
Arterioscler Thromb Vasc Biol. 2020 Sep;40(9):2002-2017. doi: 10.1161/ATVBAHA.120.314222. Epub 2020 Jul 23.
Despite major advances in the primary and secondary prevention of atherosclerosis and its risk factors, atherosclerotic cardiovascular disease remains a major clinical and financial burden on individuals and health systems worldwide. In addition, neointima formation and proliferation due to mechanical trauma to the vessel wall during percutaneous coronary interventions can lead to vascular restenosis and limit the longevity and effectiveness of coronary revascularization. Long noncoding RNAs (lncRNAs) have emerged as a novel class of epigenetic regulators with critical roles in the pathogenesis of atherosclerosis and restenosis following vascular injury. Here, we provide an in-depth review of lncRNAs that regulate the development of atherosclerosis or contribute to the pathogenesis of restenosis following mechanical vascular injury. We describe the diverse array of intracellular mechanisms by which lncRNAs exert their regulatory effects. We highlight the utility and challenges of lncRNAs as biomarkers. Finally, we discuss the immense translational potential of lncRNAs and strategies for targeting them therapeutically using oligonucleotide-based therapeutics and novel gene therapy platforms.
尽管在动脉粥样硬化及其危险因素的一级和二级预防方面取得了重大进展,但动脉粥样硬化性心血管疾病仍然是全球个人和卫生系统的主要临床和经济负担。此外,经皮冠状动脉介入治疗时血管壁的机械性创伤会导致新生内膜形成和增殖,从而导致血管再狭窄,并限制冠状动脉血运重建的长期效果和有效性。长链非编码 RNA(lncRNA)作为一类新型表观遗传调控因子而出现,其在动脉粥样硬化的发病机制以及血管损伤后的再狭窄中具有关键作用。在这里,我们深入综述了调节动脉粥样硬化发展或有助于机械性血管损伤后再狭窄发病机制的 lncRNA。我们描述了 lncRNA 发挥其调节作用的多种细胞内机制。我们强调了 lncRNA 作为生物标志物的实用性和挑战。最后,我们讨论了 lncRNA 的巨大转化潜力,以及使用基于寡核苷酸的治疗方法和新型基因治疗平台靶向治疗它们的策略。